Common TitleSofosbuvir-Velpatasvir in Patients with ESRD on Dialysis
Official Title Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis
Phase Phase II
ClinicalTrials.gov NCT03036852
Treatments
Sofosbuvir-Velpatasvir

Sofosbuvir-Velpatasvir
Tradename:EpclusaOther Names:SOF-VELClass:FDA-ApprovedFunding
IndustryGilead Sciences